FDA Approves Priority Review of Merck's Zolinza (Vorinostat)

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 7
Volume 15
Issue 7

FDA Approves Priority Review of Merck's Zolinza (Vorinostat)

WHITEHOUSE STATION, New Jersey—FDA has granted priority review status to Merck's New Drug Application for Zolinza (vorinostat, also known as suberoylanilide hydroxamic acid or SAHA) for the treatment of advanced cutaneous T-cell lymphoma (CTCL). A pivotal phase IIb trial showed activity in CTCL patients who had failed a median of three previous therapies. Zolinza is potentially the first in a new class of therapies, the histone deacetylase inhibitors.

Recent Videos
7 experts are featured in this series.
7 experts are featured in this series.
2 KOLs are featured in this series.
Patients with high-risk markers may especially benefit from the addition of daratumumab to lenalidomide as maintenance therapy for NDMM.
A machine learning method for scoring tumor-infiltrating lymphocytes may address variability in pathologist measurements.
Clinical trials in small cell lung cancer appear to be more “pragmatic” with their inclusion criteria than before, according to Anne Chiang, MD, PhD.
Related Content